Universitätsklinikum Essen
Universitätsklinikum Essen
Essen, North Rhine-Westphalia, Germany16 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 3 | 2026-10-02 | NCT06472245 | |
| A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 2 | 2026-09-30 | NCT07015242 | |
| A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria | Chronic Disease, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Urination Disorders, Urogenital Diseases, Urological Manifestations, chronic renal failure syndrome, kidney disorder, kidney failure, proteinuria, urinary system disorder | Recruiting | Phase 3 | 2026-09-24 | NCT05457283 | |
| A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria | Chronic Disease, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Urination Disorders, Urogenital Diseases, Urological Manifestations, chronic renal failure syndrome, kidney disorder, kidney failure, proteinuria, urinary system disorder | Active, not recruiting | Phase 3 | 2026-08-28 | NCT05196035 | |
| Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly Diagnosed NPM1 Mutated AML | Hemic and Lymphatic Diseases, Neoplasm, Residual, Neoplasms by Histologic Type, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Phase 2 | 2026-08-27 | NCT05904106 | |
| SAVR: IMPACT of Pre-existing Comorbidities on Patient Outcomes and Prosthetic Valve Performance in a Real-world Setting. | cardiovascular disorder | Active, not recruiting | Not stated | 2026-07-30 | NCT04053088 | |
| Acyclovir in Ventilated Patients With Pneumonia and HSV-1 in BAL | Community-Acquired Infections, Community-Acquired Pneumonia, DNA Virus Infections, Disease Attributes, Healthcare-Associated Pneumonia, Herpesviridae infectious disease, Infections, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Pneumonia, Ventilator-Associated, Skin Diseases, Viral, Skin and Connective Tissue Diseases, herpes simplex infectious disease, iatrogenic disease, lung disorder, nosocomial infection, pneumonia, respiratory system disorder, respiratory tract infectious disorder, skin disorder, skin disorder caused by infection, viral infectious disease, viral pneumonia | Recruiting | Phase 3 | 2026-07-23 | NCT06134492 | |
| A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Eye Diseases, Hereditary, Graves Ophthalmopathy, Graves disease, autoimmune disease, disease of orbital part of eye adnexa, endocrine system disorder, exophthalmos, eye disorder, goiter, hereditary disease, hyperthyroidism, immune system disorder, thyroid gland disorder | Active, not recruiting | Phase 3 | 2026-07-07 | NCT06248619 | |
| Neoadjuvant Merkel Cell Carcinoma Therapy (Tx) With the PD-1 Inhibitor Cemiplimab | DNA Virus Infections, Infections, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, Tumor Virus Infections, adenocarcinoma, carcinoma, cutaneous neuroendocrine carcinoma, epithelial neoplasm, neoplasm, neuroendocrine carcinoma, neuroendocrine neoplasm, polyomavirus infectious disease, primitive neuroectodermal tumor, skin disorder, skin neoplasm, viral infectious disease | Recruiting | Phase 2 | 2026-06-22 | NCT07387198 | |
| Neoadjuvant Darovasertib in Primary Uveal Melanoma | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, Uveal Neoplasms, eye disorder, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, ocular cancer, primitive neuroectodermal tumor, skin disorder, skin neoplasm, uveal disorder, uveal melanoma | Recruiting | Phase 3 | 2026-05-06 | NCT07015190 | |
| Sacituzumab Govitecan in Primary HER2-negative Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Active, not recruiting | Phase 3 | 2026-04-22 | NCT04595565 | |
| ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study) | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, epithelial neoplasm, glioma, neoplasm, neuroepithelial neoplasm, primitive neuroectodermal tumor | Recruiting | Phase 3 | 2026-04-16 | NCT05580562 | |
| Efficacy and Safety of Standard of Care Plus Durvalumab in Patients With Limited Disease Small Cell Lung Cancer (DOLPHIN) | Neoplasms by Site, Thoracic Neoplasms, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 2 | 2026-02-27 | NCT04602533 | |
| T-cell Therapy in Patients With PML | DNA Virus Infections, Encephalitis, Viral, Infections, Leukoencephalopathies, Neuroinflammatory Diseases, Slow Virus Diseases, brain disorder, central nervous system disorder, central nervous system infectious disorder, demyelinating disease, encephalitis, infectious encephalitis, nervous system disorder, polyomavirus infectious disease, progressive multifocal leukoencephalopathy, viral infection of central nervous system, viral infectious disease | Recruiting | Phase 2 | 2026-02-12 | NCT06990087 | |
| Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC) | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Phase 1 / Phase 2 | 2025-09-08 | NCT04385290 | |
| A Post Market Surveillance Study of the Hemovent Extracorporeal Cardiopulmonary Support System:The MOBYBOX Trial | Respiration Disorders, cardiovascular disorder, heart disorder, heart failure, respiratory failure, respiratory system disorder | Recruiting | Not stated | 2025-05-31 | NCT04183660 |